The role of glutamate receptor maturation in perinatal seizures and brain injury.
The perinatal age window is characterized by vulnerability to age-specific patterns of injury. Hypoxia/ischemia occurs in a number of settings both in term and preterm neonates, yet the patterns of response appear dependent upon the age of the infant. In the preterm neonate, hypoxic/ischemic insults result in selective white matter injury, termed periventricular leukomalacia (PVL), with little or no cortical pathology. However, in term babies, hypoxic encephalopathy is the most common cause of seizures, and also can result in cortical infarction. Extracellular glutamate accumulates in the setting of hypoxia/ischemia, and excess activation of glutamate receptors has been implicated in hypoxic/ischemic cellular death. Glutamate receptors are developmentally regulated in both neuronal and glial cells within the brain. Using rodent models, we have shown that hypoxia/ischemia results in selective white matter injury in postnatal day (P) seven rat pups, while hypoxia causes seizures in P10-12 rats, but not at younger or older ages. We have further demonstrated that antagonists of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptor subtype block white matter injury at P7 and seizures at P10. We have shown that AMPA receptors are relatively overexpressed in oligodendrocytes (OLs) within white matter at P7 and in neurons in cortex and hippocampus at P10. Hence maturational patterns of glutamate receptor expression correlate with age-specific regional susceptibility to injury to hypoxia/ischemia. While glutamate receptor blockade represents a rational strategy in the treatment of perinatal hypoxic/ischemic brain injury, it is unclear what role variations in their expression play in normal development and plasticity. Further investigation of patterns of glutamate receptor subunit expression in human brain and in experimental animal models is necessary to determine potential age specific strategies as well as adverse effects.
Jensen
Frances E
FE
Program in Neuroscience, Department of Neurology, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. frances.jensen@tch.harvard.edu
D000818:Animals; D001238:Asphyxia Neonatorum / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D001930:Brain Injuries / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D002540:Cerebral Cortex / Q000254:growth & development* / Q000378:metabolism / Q000503:physiopathology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D007231:Infant, Newborn; D007969:Leukomalacia, Periventricular / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism; D011247:Pregnancy; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors / Q000378:metabolism*; D012640:Seizures / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology
D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA